1Riley RD,Heney D,Jones DR,et al.A systematic review of molecular and biological tumor markers in neuroblastoma.Clin Cancer Res,2004,10(1) :4 - 12.
2Crabbe DC,Peters J,Seeger RC.Rapid detection of MYCN gene amplification in neuroblastomas using the polymerase chain reaction.Diagn Mol Pathol,1992,1(4):229- 234.
3White PS,Thompson PM,Gotoh T,et al.Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma.Oncogene,2005,24(16):2684- 2694.
4Bown N,Lastowska M,Cotterill S,et al.17q gain in neuroblastoma predicts adverse clinical outcome.UK Cancer Cytogenetics Group and the UK Childrens's Cancer Study Group.Med Pediatr Oncol,2001,36(1):14- 19.
5Shimada H,Nakagawa A,Peters J,et al.TrkA expression in peripheral neuroblastic tumors:prognostic significance and biological relevance.Cancer,2004,101(8):1873 - 1881.
6Shimada H.The international neuroblastoma pathology classification.Pathologica,2003,95(5):240 - 241.
7Goto S,Umehara S,Gerbing RB,et al.Histopathology (International Neuroblastoma Pathology Classification)and MYCN status in patients with peripheral neuroblastic tumors:a report from the Children's Cancer Group.Cancer,2001,92(10):2699 - 2708.
8Schmidt ML,Lukens JN,Seeger RC,et al.Biologic factors determine prognosis in infants with stage Ⅳ neuroblastoma:a prospective Children' s Cancer Group study.J Clin Oncol,2000,18(6) :1260 - 1268.
9Seeger RC,Reynolds CP,Gallego R,et al.Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage Ⅳ neuroblastoma:a Children's Cancer Group Study.J Clin Oncol,2000,18(24):4067- 4076.
10Matthay KK,O' Leary MC,Ramsay NK,et al.Role of myeloablative therapy in improved outcome for high risk neuroblastoma:review of recent Children's Cancer Group results.Eur J Cancer,1995,31A(4):572-575.
